Effective Therapy of Insulinoma by Using Long-Acting Somatostatin Analogue. A Case Report and Literature Review

 

 Buy Article Permissions and Reprints

Abstract

We are reporting a case of 68-year-old woman with insulinoma, after a non-successful tumor surgery and a long-term diazoxide treatment. She had a lot of hypoglycemia cases, and a weight gain of 50 kg. An abdominal CT scan demonstrated a tumor 28 mm in the diameter, in the head of the pancreas. The patient did not agree for the repeated insulinoma surgery. Furthermore, we found a lesion in the left adrenal gland (14 mm in the diameter) and in the right lung (8 mm in the diameter). Pheochromocytoma was diagnosed on the basis of hypertension, elevated levels of normetanephrine in the 24-h urine collection, and an elevated level of norepinephrine in a plasma sample. After the left adrenal gland removal we observed lower blood pressure. Since we had revealed the presence of somatostatin receptors by the somatostatin receptors scintigraphy, we decided to control hypoglycemia by a monthly subcutaneous administration of the long-acting lanreotide. Because of higher glucose levels (300–400 mg/dl) we started an intense insulin therapy. Nowadays, the patient feels better, she has lost 20 kg of her body weight, and we have observed normal blood glucose levels during the long-term lanreotide treatment. We have noticed neither side effects nor hypoglycemic episodes and we have reduced the dose of insulin. The presented case can be an evidence of the effective treatment of the pancreatic neuroendocrine tumor of insulinoma type, with somatostatin analogue.

• References

• 1 Berends FJ, Cuesta MA, Kazemier G et al. Laparoscopic detection and resection of insulinomas. Surgery 2000; 128: 386-391
  CrossrefPubMedGoogle Scholar
• 2 Bertherat J, Tenenbaum F, Perlemoine K et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: An in vivo and in vitro study. J Clin Endocrinol Metab 2003; 88: 5353-5360
  CrossrefPubMedGoogle Scholar
• 3 Caron P, Cogne M, Raingeard I et al. Effectiveness and tolerability of: 3-year Lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol 2006; 64: 209-214
  CrossrefPubMedGoogle Scholar
• 4 de Herder WW, Kwekkeboom DJ, Valkeme R et al. Neuroendocrine tumors and somatostatyn: imaging techniques. Neuroendocrinology 2005; 28: 132-136
  PubMedGoogle Scholar
• 5 de Herder WW, Niederle B, Scoazec JY. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006; 84: 184-188
  PubMedGoogle Scholar
• 6 Goode PN, Farndon JR, Anderson J et al. Diazoxide in the management of patients with insulinoma. World J Surg 1986; 10: 586-592
  CrossrefPubMedGoogle Scholar
• 7 Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol 2005; 19: 783-798
  CrossrefPubMedGoogle Scholar
• 8 Katabami T, Kato H, Shirai N et al. Successful long-term treatment with once-daily injection of low-dose octreotide in an aged patient with insulinoma. Endocr J 2005; 52: 629-634
  CrossrefPubMedGoogle Scholar
• 9 Kondo T, Tomita S, Adachi H et al. A case of hyperinsulinemia of undetermined origin, successfully treated with long-acting octreotide. Endocr J 2005; 52: 511-517
  CrossrefPubMedGoogle Scholar
• 10 Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12: 450-482
  CrossrefPubMedGoogle Scholar
• 11 Moscetti L, Saltarelli R, Giuliani R et al. Intra-arterial liver chemotherapy and hormone therapy in malignant insulinoma: Case report and review of the literature. Tumori 2000; 86: 475-479
  PubMedGoogle Scholar
• 12 Novotny J, Janku F, Mares P et al. Symptomatic control of hypoglycemia with prednisone in refractory metastatic pancreatic insulinoma. Support Care Cancer 2005; 13: 760-762
  CrossrefPubMedGoogle Scholar
• 13 Romeo S, Milione M, Gatti A et al. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. Horm Res 2006; 65: 120-125
  CrossrefPubMedGoogle Scholar
• 14 Tolis G, Angelopoulos NG, Katounda E et al. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin. Neuroendocrinology 2006; 83: 249-257
  CrossrefPubMedGoogle Scholar
• 15 Usukura M, Yoneda T, Oda N et al. Medical treatment of benign insulinoma using octreotide LAR: a case report. Endocr J 2007; 54: 95-101
  CrossrefPubMedGoogle Scholar
• 16 Vezzosi D, Bennet A, Courbon F et al. Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia to endogenous hyperinsulinism. Clin Endocrinol 2008; 68: 904-911
  CrossrefPubMedGoogle Scholar
• 17 Vezzosi D, Bennet A, Rochaix P et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 2005; 152: 757-767
  CrossrefPubMedGoogle Scholar
• 18 Yamada Y, Kagimoto S, Kubota A et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 1993; 195: 844-852
  CrossrefPubMedGoogle Scholar